[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 3, 2002

The Costs of Making Practice More Cost-effective

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(13):1648-1650. doi:10.1001/jama.287.13.1645

To the Editor: Dr Mason and colleagues1 assert that "newer classes of antidepressants have achieved widespread first-line use without demonstrating added value." In a recent study, however, Kroenke et al2 stated that "compared with tricyclic antidepressants, selective serotonin reuptake inhibitors have a more favorable adverse effect profile, simpler dosing, and less toxic effects in the event of an overdose," while demonstrating effectiveness equal to tricyclic antidepressants. The contrast between assumptions of these 2 articles raises questions about the kind of evidence that should be considered in making these judgments.

First Page Preview View Large
First page PDF preview
First page PDF preview
×